Core Insights - Haleon plc (NYSE:HLN) is experiencing mixed performance, with struggles in North America but strong growth in Latin America and India [2] - The company reported a 0.4% growth in US same-store sales, contrasting with the 1.4% decline that analysts had predicted, indicating a tight consumer economy [2] - Haleon's defensive product line, Sensodyne, saw revenue growth, while discretionary brands experienced a drop in sales [2] - Jim Cramer suggested that Haleon could be likened to a "mini Kenvue," highlighting its potential without the controversies associated with Kenvue [3] Company Performance - Haleon plc sells consumer products, including toothpaste and pain relief items, under well-known brands like Sensodyne and Panadol [2] - The third-quarter earnings report showed a 0.4% increase in US same-store sales, which was better than the expected 1.4% decrease [2] - The performance in North America contrasts with the strong growth in other regions, particularly Latin America and India [2] Market Position - The company is positioned in a tight consumer economy, with mixed results across its product lines [2] - Cramer’s commentary suggests that Haleon has potential as an investment, although there are other AI stocks that may offer higher returns [3]

Core Viewpoint - The article emphasizes the strategic opportunities in China's pharmaceutical and healthcare sector, particularly in the context of the "14th Five-Year Plan" and the upcoming "15th Five-Year Plan," highlighting the importance of health in national development and the need for enhanced public health initiatives [1]. Policy and Strategic Initiatives - The "15th Five-Year Plan" proposes a health-first development strategy, aiming to increase the average life expectancy in China from 79 years in 2024 to around 80 years [1]. - The 8th China International Import Expo (CIIE) showcased cutting-edge technologies and innovative products in the healthcare sector, indicating a strong response from the industry to policy initiatives [1]. Chronic Disease Management - Cardiovascular diseases remain a significant health threat in China, with over 330 million patients, and low awareness and treatment rates for blood lipid management [3]. - Collaborative efforts, such as the "Super Consultation" event by Tencent News and Novartis, aim to address public misconceptions about LDL-C and improve cardiovascular disease management [3]. Innovations in Disease Prevention - GSK is focusing on product innovation and health education to promote the prevention of diseases closely related to chronic conditions, such as shingles, which poses increased risks for patients with cardiovascular diseases [4][5]. - Bayer introduced a new product for chronic constipation management, addressing a prevalent health issue among adults in China [5]. Retail Health Services - The retail sector is crucial in connecting healthcare services with public health, with initiatives to extend health services from hospitals to homes [7]. - Novo Nordisk and the China Pharmaceutical Commerce Association launched a health management standard for obesity in retail pharmacies, aiming to enhance patient support [7][9]. AI in Healthcare - AI technology is increasingly integrated into healthcare, enhancing clinical diagnosis and patient management, as demonstrated by various companies at the CIIE [13]. - The launch of AI-driven platforms, such as Boston Scientific's medical knowledge graph, aims to improve clinical education and decision-making [13][14]. Ecosystem Collaboration - The CIIE serves as a platform for collaboration among healthcare companies, fostering partnerships that enhance innovation and market access [18]. - Companies like Merck and Medtronic are focusing on local partnerships to accelerate the introduction of innovative products in China [19][20]. Conclusion - The healthcare sector in China is undergoing significant transformation driven by policy support, technological advancements, and collaborative efforts among industry players, aiming to improve public health outcomes and enhance the overall healthcare ecosystem [1][18].

Core Points - The conference call is focused on Haleon's third quarter trading statement for 2025 [1] - Jo Russell, Head of Investor Relations, and Dawn Allen, CFO, are leading the discussion [1] Company Overview - The company is expected to provide forward-looking statements regarding estimates, plans, and expectations during the call [2] - Listeners are reminded to refer to the company's announcements and filings for more details on potential discrepancies in actual results [2] Q&A Session - After the remarks from the CFO, a question-and-answer session will be held for participants [3] - Dial-in details for the webcast audience are provided in the press release [3]

Financial Data and Key Metrics Changes - The company achieved 3.4% organic revenue growth in Q3, with a balance of 1.8% from price and 1.6% from volume mix [3][6] - Reported revenue grew by 0.7% in Q3, impacted by a 2.3% drag from divestments and a 0.4% impact from foreign exchange [6][7] - The company is on track to deliver its full-year guidance, expecting organic revenue growth of around 3.5% for 2025 [15][16] Business Line Data and Key Metrics Changes - Oral health grew by 6.9% in Q3, driven by innovation-led premiumization and geographic expansion [7][8] - The business line for pain relief grew by 3.7%, with Panadol showing high single-digit growth [8][9] - Respiratory health declined by 1.8%, while digestive health grew by 2.1% [9][10] Market Data and Key Metrics Changes - North America delivered organic revenue growth of 0.4%, driven by a 0.7% price increase, while volume mix decreased by 0.3% [10][12] - EMEA and LATAM saw organic revenue increase of 5.3%, with price growth at 3.5% and volume mix improvement of 1.8% [12][13] - Asia-Pacific experienced organic revenue growth of 5.1%, with strong performance in India and Southeast Asia [13][14] Company Strategy and Development Direction - The company is focusing on innovation-led premiumization to drive category growth and has made significant progress in its supply chain productivity agenda [5][6] - The company aims to strengthen its innovation pipeline and improve net revenue management through strategic pricing and channel mix [11][12] - The company is closely monitoring the macroeconomic environment in Latin America and expects to adapt its strategies accordingly [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth in North America next year, citing actions taken to improve inventory management and innovation pipeline [21][22] - The company anticipates continued strong growth in Q4, driven by salesforce investment and an improving macro environment [14][15] - Management noted that the consumer health market remains resilient despite macroeconomic pressures, particularly in oral health [58][59] Other Important Information - The company has completed EUR 500 million in share buybacks for 2025 [6] - The company reduced the number of SKUs by 19% since the beginning of 2024, improving gross margin and cash conversion [5][6] Q&A Session Summary Question: North America performance and future expectations - Management noted that the performance in North America was better than expected, driven by oral health and digestive health, with no significant one-offs affecting Q3 results [20][21] Question: Innovation pipeline for 2026 - The company highlighted a strong innovation pipeline across all categories, with no immediate need for RX to OTC switches impacting growth forecasts [28][29] Question: Pricing evolution in EMEA and LATAM - Management acknowledged competitive pressures leading to increased promotional activity, particularly in VMS, while maintaining resilience in oral health [47][72] Question: Category performance and consumer behavior - Management observed a bifurcated consumer environment, with some categories performing well while others struggled, emphasizing the importance of being present across all channels [41][42] Question: Inventory management and channel dynamics - Management confirmed that inventory levels are being adjusted based on consumption trends, with a focus on exiting the year in a clean position [36][66]

Financial Data and Key Metrics Changes - The company achieved 3.4% organic revenue growth in Q3, with a balance of 1.8% from price and 1.6% from volume mix [3][6] - Reported revenue grew 0.7% in Q3, impacted by a 2.3% drag from divestments and 0.4% from foreign exchange [6][7] - The company is on track to deliver its full-year guidance, expecting organic revenue growth of around 3.5% for 2025 [15][16] Business Line Data and Key Metrics Changes - Oral health grew 6.9% in Q3, driven by innovation-led premiumization and geographic expansion [7][8] - The business line for pain relief grew 3.7%, with Panadol showing high single-digit growth [8][9] - Respiratory health declined 1.8%, influenced by the previous year's elevated COVID cases [9][10] - Digestive health grew 2.1%, supported by innovations like TUMS Gummy Bites Plus [9][10] Market Data and Key Metrics Changes - North America delivered organic revenue growth of 0.4%, driven by 0.7% price increase, while volume mix decreased by 0.3% [10][12] - EMEA and LATAM saw organic revenue increase of 5.3%, with price at 3.5% and volume mix at 1.8% [12][13] - Asia-Pacific experienced organic revenue growth of 5.1%, with strong performance in India and Southeast Asia [13][14] Company Strategy and Development Direction - The company focuses on innovation-led premiumization to drive category growth and expand market reach [4][6] - Continued investment in supply chain productivity and cost discipline is emphasized to enhance flexibility and agility in P&L [5][6] - The company aims to strengthen its innovation pipeline and improve net revenue management in North America [11][22] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging consumer backdrop in North America but highlighted outperformance in oral health and digestive health [3][10] - The company expects continued strong growth in Q4, driven by salesforce investment and an improving macro environment [14][15] - Management remains confident in returning to growth in North America next year, with actions in place to address inventory levels [22][66] Other Important Information - The company completed EUR 500 million in share buybacks for 2025 [6] - Significant progress has been made in reducing SKUs by 19%, improving gross margin and working capital [5][80] Q&A Session Summary Question: North America performance and future expectations - Management explained that the sequential improvement in North America was driven by reduced drag from smokers' health and better performance in oral and digestive health [20][21] - Guidance for Q4 suggests around 1% decline, reflecting tough comparatives from the prior year [21][22] Question: Innovation pipeline and cold/flu season outlook - Management confirmed a strong innovation pipeline across categories and noted that the cold and flu season's variability impacts guidance [28][30] Question: Channel dynamics and inventory management - Management discussed the differences in inventory levels across channels, with a focus on ensuring appropriate stock levels for growth next year [35][66] Question: Consumer behavior and market performance - Management highlighted a bifurcated consumer environment, with varying performance across categories and channels [41][42] Question: Oral care business performance - Management acknowledged softer performance in certain oral care brands but remains positive about overall oral health growth [70][72]

Financial Data and Key Metrics Changes - The company achieved 3.4% organic revenue growth in Q3, with a balance of 1.8% from price and 1.6% from volume mix [3][6] - Reported revenue grew by 0.7% in Q3, affected by a 2.3% drag from divestments and a 0.4% impact from foreign exchange [6][7] - The company is on track to deliver its full-year guidance, expecting organic revenue growth of around 3.5% for 2025 [15][16] Business Line Data and Key Metrics Changes - Oral health grew by 6.9% in Q3, driven by innovation and geographic expansion, particularly in markets like the US, India, and China [7][10] - The BMS category grew by 4.9% in Q3, with strong performance from Centrum [8] - Pain relief grew by 3.7%, with Panadol showing high single-digit growth, while respiratory health declined by 1.8% [8][9] - Digestive health grew by 2.1%, supported by innovations in TUMS and Benefiber [9] Market Data and Key Metrics Changes - North America delivered organic revenue growth of 0.4%, driven by oral health and digestive health, despite challenges in the respiratory category [10][11] - EMEA and LATAM saw organic revenue increase of 5.3%, with strong performance in oral health and VMS [11][12] - Asia-Pacific experienced organic revenue growth of 5.1%, with double-digit growth in India and strong performance in Southeast Asia [12][14] Company Strategy and Development Direction - The company is focused on driving category growth through innovation-led premiumization and expanding reach to lower-income consumers [4][5] - Continued investment in supply chain productivity and cost discipline is expected to enhance flexibility and agility in the P&L [5][6] - The company aims to return to growth in North America next year, supported by a strong innovation pipeline and strategic pricing initiatives [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong growth in Q4, driven by salesforce investment and an improving macro environment [14][15] - The company is closely monitoring the macroeconomic environment in Latin America due to consumer pressures [16] - Management highlighted the resilience of the oral health category and the importance of being present across all channels to cater to changing consumer behaviors [41][57] Other Important Information - The company has completed £500 million in share buybacks for 2025 [6] - Significant progress has been made in reducing SKUs by 19%, which is expected to improve gross margin and working capital [5][78] Q&A Session Summary Question: North America performance and future expectations - Management noted that the performance in North America was better than expected, driven by oral health and digestive health, with no one-off benefits impacting Q3 [19][20] - For Q4, a slight decline in organic sales growth is anticipated due to tough comparatives from the prior year [21][22] Question: Innovation pipeline and cold/flu season outlook - The company has a strong innovation pipeline across categories, with no immediate RX to OTC switches expected [27][29] - Guidance for the cold and flu season is based on a normal season assumption, with variability expected [30][31] Question: Consumer behavior and channel dynamics - Management observed a bifurcated consumer environment, with some products performing well while others struggle, and emphasized the importance of being present across all shopping channels [41][42] Question: Pricing evolution in EMEA and LATAM - Management indicated that competitive pressure and promotional activity have increased due to softer consumption, impacting pricing in EMEA and LATAM [46][47] Question: Contribution of innovations and pain franchise performance - Innovations have significantly contributed to growth, with ongoing launches expected to drive future performance [53][54]

2025 Third quarter trading statement October 2025 Disclaimer This presentation contains certain statements that are, or may be deemed to be, "forward-looking statements" (including for purposes of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements give Haleon's current expectations and projections about future events, including strategic initiatives and future fin ...

Core Insights - Haleon reported third-quarter organic revenue growth that was slightly above market estimates, driven by strong demand for its oral health products [1] Company Summary - The British consumer healthcare group Haleon has shown resilience in its revenue performance, indicating a positive market response to its product offerings, particularly in the oral health segment [1]

Core Viewpoint - Haleon plc (NYSE:HLN) is recognized as one of the best growth stocks under $25, with analysts maintaining positive ratings and growth forecasts for the company [1][2]. Group 1: Analyst Ratings and Price Targets - Jefferies analyst David Hayes maintains a Buy rating on Haleon plc with a price target of p440 [1]. - Barclays analyst Warren Ackerman holds a Hold rating on Haleon plc with a price target of p380 [3]. Group 2: Growth Forecasts - The company is expected to see improved performance due to easier sales comparisons in Latin America, positive innovation impacts in Europe and emerging markets, and stabilization in North America [2]. - Organic sales are forecasted to grow at 3.4% during FQ3 2025, with an increased forecast of 3.6% growth in FQ4 [2]. - Analysts remain optimistic about Haleon plc's growth potential, anticipating acceleration in growth for 2026 [2]. Group 3: Company Overview - Haleon plc is a consumer healthcare company that offers a diverse range of products across six major categories: oral health, vitamins, pain relief, respiratory, digestive, and skin health [3].

Core Insights - Haleon plc, a leading global consumer company specializing in everyday health, has partnered with Salesforce to enhance engagement with pharmacies and healthcare professionals globally [1] - The collaboration will utilize Salesforce Life Sciences Cloud for Customer Engagement, Data Cloud, and Agentforce to support Haleon's global sales force of 4,500 [1] Company Overview - Haleon plc focuses on consumer health products and aims to improve its operational efficiency through advanced technology [1] - Salesforce, recognized as the world's 1 AI CRM, will provide the necessary tools to facilitate better customer interactions for Haleon [1] Technology Utilization - The integration of Salesforce's AI-powered solutions is expected to drive more effective engagement strategies within Haleon's sales operations [1] - The specific tools being implemented include Salesforce Life Sciences Cloud, which is tailored for the life sciences sector, enhancing customer engagement capabilities [1]